Drug Trial Radar · NCT06021197
NMDA-enhancing Treatment for Cognitive Dysfunction of Schizophrenia
Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
90
Planned (sponsor's estimate)
Start
Oct 12, 2023
Primary completion
Dec 2027
Study completion Mar 2028
Sponsor
- Lead sponsor
- China Medical University HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Science and Technology Council, Taiwan
- First posted
- Sep 1, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Cognitive impairment, the core psychopathology of schizophrenia, usually persists in schizophrenia patients even during symptomatic remission. While cognitive impairment associated with schizophrenia (CIAS) is an important therapeutic target, hypofunction of N-methyl-D-aspartate receptor (NMDAR) is a key factor of CIAS. This study aims to examine the efficacy and safety of an NMDA-enhancer (NMDAE) for the treatment of CIAS in schizophrenia patients during symptomatic remission.
Conditions
- Schizophrenia
Interventions
NMDAEDrug
Use of an NMDA enhancer for the treatment of CIAS
Placebo CapDrug
Use of placebo as a comparator
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change of cognitive function compositeTime frame: Week 0, 12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Department of Psychiatry, China Medical University Hospital
Taichung, Taiwan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.